Ingevity posts FY 2025 net loss of USD 167.1 million on USD 1.3 billion net sales -8%

Reuters
Feb 26
Ingevity posts FY 2025 net loss of USD 167.1 million on USD 1.3 billion net sales -8%

Ingevity reported FY 2025 and Q4 2025 results, including continuing and discontinued operations. FY net sales were USD 1.3 billion (-8%), with a net loss of USD 167.1 million and diluted loss per share of USD 4.61, driven primarily by USD 293.1 million in non-cash pre-tax special charges related to Advanced Polymer Technologies and Road Markings. FY total adjusted EBITDA was USD 397.5 million (+10%), with a 30.8% margin; operating cash flow was USD 331.2 million and free cash flow was USD 273.5 million, with net leverage at 2.6x. In Q4, total net sales were USD 278.0 million (-7%), with a net loss of USD 84.6 million and diluted loss per share of USD 2.37, largely driven by USD 109.3 million in pre-tax non-cash special charges related to Road Markings. Q4 total adjusted EBITDA was USD 75.0 million; operating cash flow was USD 97.1 million and free cash flow was USD 73.5 million. Ingevity said it completed the sale of its North Charleston crude tall oil refinery assets and the majority of the Performance Chemicals Industrial Specialties product line, concluded a portfolio review, and began exploring strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings product line. The company also repurchased USD 56 million of shares in FY 2025 and ended the year with USD 297 million remaining under its current authorization. For FY 2026, Ingevity guided net sales of USD 1.1 billion to USD 1.2 billion, adjusted EBITDA of USD 380 million to USD 400 million, adjusted EPS of USD 4.80 to USD 5.20, and free cash flow of USD 225 million to USD 250 million, excluding approximately USD 95 million in pre-tax litigation-related payments to BASF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingevity Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602251615BIZWIRE_USPR_____20260225_BW113545) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10